Adam’s Take
Insights and opinions from senior biotech writer Adam Feuerstein
Most Read
STAT Plus: A company developing a human blood substitute attempts a comeback, but IPO plans look dicey
STAT Plus: What Regeneron’s purchase of Checkmate Pharma says about the state of biotech
STAT Plus: Cel-Sci’s CEO used private call to tip off select investors about cancer drug update
STAT Plus: Troubles mount for Cassava Sciences, as patient enrollment lags for Alzheimer’s drug studies
STAT Plus: Aurinia Pharma’s takeout hopes dim with new legal challenge to key drug patent
STAT Plus: Northwest Bio marks ignominious anniversary of brain tumor study delay with silence
STAT Plus: In new remarks, Cassava Sciences’ CEO shifts defense of embattled treatment for Alzheimer’s
All Coverage
advertisement
